Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of ...

Objectives This study aims to study the association between socioeconomic factors and risk of prevalent eye diseases, ...

They also will evaluate advances in imaging and current and emerging therapies for the treatment and management of retinal vein occlusion. Upon successful completion of this educational activity ...

Insights, Trends, Opportunities, and Recent DevelopmentsNew York, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Market Overview The global occlusion devices market is projected to reach USD 4.0 billion by 2024 ...

Twenty-five patients were excluded from the study because of refractory ascites in two, a 24-h creatinine clearance <40 mL/min in three, a platelet count <20 000/mm 3 in one, portal vein ...

High blood pressure, stress, sun exposure, vein dysfunction, pregnancy, and other factors can contribute to the appearance of veins on the forehead. Genetic factors or age can influence whether ...

As you get older, it’s not uncommon to notice large, twisty veins forming on your legs. According to the Society for Vascular Surgery, as many as 40 million Americans have what are known as varicose ...